243 completed, 91 terminated, 61 active not recruiting, 30 recruiting. 292 Phase 2, 187 Phase 1, 57 Phase 3, 6 Early Phase 1, 4 Not applicable.
Follow Revlimid: new trials by email Literature Review of Revlimid trials Research Report on Revlimid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-26 |
| Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype Dexamethasone, Bortezomib, LENALIDOMIDE - Multiple Myeloma, Triple Negative Breast Cancer | Phase 1 | Recruiting | Andrew Hantel, MD | 90 | 2026-07-30 | 2026-08-17 |
| Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level Daratumumab, Lenalidomide, Dexamethasone - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | Phase 3 | Recruiting | University of Leeds | 1226 | 2026-07-01 | 2026-07-15 |
| Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients Isatuximab, Bortezomib, Lenalidomide - Multiple Myeloma | Recruiting | Shanghai Zhongshan Hospital | 333 | 2026-06-01 | 2026-06-23 | |
| Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-10-07 | 2026-10-21 |
| Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma Elranatamab, Daratumumab, Lenalidomide - Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM) | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 100 | 2025-08-08 | 2026-06-04 |
| Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Epcoritamab - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder | Phase 2 | Recruiting | Reem Karmali | 34 | 2025-07-25 | 2026-07-08 |
| VitD3 Supplementation in Patients With Multiple Myeloma Lenalidomide, Maintenance Vitamin D, No maintenance Vitamin D - Multiple Myeloma | Early Phase 1 | Recruiting | Amany Keruakous, MD, MS. | 100 | 2024-12-01 | 2025-04-08 |
| Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant Belantamab Mafodotin, Lenalidomide - Plasma Cell Myeloma | Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 4 | 2024-08-19 | 2026-10-16 |
| Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma Dexrazoxane, Rituximab, Cyclophosphamide - DLBCL - Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 324 | 2024-08-15 | 2026-09-23 |
| Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 58 | 2024-07-23 | 2026-09-25 |
| Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Lenalidomide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-05-20 | 2026-10-26 |
| Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients. Lenalidomide, Obinutuzumab Injection [Gazyva] - Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 1 / Phase 2 | Recruiting | Vitebsk Regional Clinical Cancer Centre | 24 | 2024-05-14 | 2026-08-13 |
| MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma | Phase 1 | Active not recruiting | Mayo Clinic | 16 | 2024-04-11 | 2026-08-17 |
| Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Follicular Lymphoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 29 | 2024-01-24 | 2026-08-26 |
| Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant Selinexor, Lenalidomide, Dexamethasone - Multiple Myeloma, Myeloma-Associated Amyloidosis | Phase 2 | Withdrawn | Washington University School of Medicine | 2024-01-05 | 2024-07-10 | |
| Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 100 | 2024-01-04 | 2024-11-18 |
| A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma Odronextamab, Lenalidomide, Rituximab - Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 580 | 2023-12-28 | 2026-10-07 |
| Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma Daratumumab, Carfilzomib, Lenalidomide - Multiple Myeloma, Primary Plasma Cell Leukemia | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 54 | 2023-10-20 | 2025-04-16 |
| A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation idecabtagene vicleucel, Lenalidomide, Fludarabine - Multiple Myeloma | Phase 3 | Active not recruiting | Celgene | 79 | 2023-10-16 | 2026-03-05 |
Showing 20 of 470. Sign in to see all of them.
Multiple Myeloma (179) · Leukemia, Lymphocytic, Chronic, B-Cell (60) · Lymphoma, Follicular (34) · Lymphoma, Mantle-Cell (34) · Lymphoma, Large B-Cell, Diffuse (33) · Myelodysplastic Syndromes (32) · Lymphoma (25) · Lymphoma, B-Cell, Marginal Zone (24) · Recurrence (24) · Lymphoma, Non-Hodgkin (23) · Leukemia (20) · Neoplasms, Plasma Cell (20) · Leukemia, Myeloid, Acute (19) · Lymphoma, B-Cell (14) · Smoldering Multiple Myeloma (14)
M.D. Anderson Cancer Center (52) · National Cancer Institute (NCI) (48) · Celgene (29) · Mayo Clinic (19) · Celgene Corporation (10) · Dana-Farber Cancer Institute (10) · Weill Medical College of Cornell University (9) · City of Hope Medical Center (8) · Massachusetts General Hospital (8) · Washington University School of Medicine (8) · Oncotherapeutics (6) · Emory University (5) · Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH (5) · SCRI Development Innovations, LLC (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5)
United States (353) · Germany (40) · France (35) · Italy (34) · Spain (31) · Canada (30) · United Kingdom (27) · Belgium (24) · Australia (21) · Austria (18) · Israel (18) · Poland (16) · China (13) · Sweden (13) · Netherlands (12)
Robert Knight, MD (6) · Ravi Vij, M.D. (5) · James R Berenson, MD (4) · Bruno Carneiro de Medeiros (3) · Joseph M Tuscano (3) · Shaji Kumar (3) · Sikander Ailawadhi, M.D. (3) · Alessandra Ferrajoli (2) · Alessandra Ferrajoli, MD,BS (2) · Amit K Verma (2) · Andrzej Jakubowiak, MD (2) · Antonio Palumbo, MD (2) · Bruce D Cheson, MD (2)
PMID 23834234, PMID 29358183, PMID 39319495, PMID 18799726, PMID 18824593, PMID 19901114, PMID 21273172, PMID 26181891, PMID 35285981, PMID 35549810, PMID 35787017, PMID 35952327, PMID 37990162, PMID 38652812, PMID 39321347, PMID 39374535, PMID 41915772, PMID 18032762, PMID 18032763, PMID 18334676, PMID 19118065, PMID 19182205, PMID 19332768, PMID 19853510, PMID 19965642, PMID 20651074, PMID 20724537, PMID 21051557, PMID 21109690, PMID 21149673, PMID 21228334, PMID 21504290, PMID 21551228, PMID 21596852, PMID 21719884, PMID 21725050, PMID 21753188, PMID 21812019, PMID 21816833, PMID 21860025, PMID 21937701, PMID 22033493, PMID 22292853, PMID 22517904, PMID 22571200, PMID 22571201, PMID 22571202, PMID 22689675, PMID 22816680, PMID 22936658
U10CA180820 (10), P30CA015083 (8), U10CA180821 (8), 2009 (7), U10CA021115 (7), U10CA180888 (7), 2008 (6), P30CA016058 (5), U01CA076576 (5), U10CA031946 (5), P30CA016672 (4), U10CA032102 (4), U24CA196172 (4), 2015 (3), P30CA014599 (3)